{"celex_id": "32012D0622(02)", "uri": "http://publications.europa.eu/resource/cellar/8fa52e71-bc53-11e1-b84a-01aa75ed71a1", "type": "Decision", "concepts": ["3586", "5916", "6059", "8465"], "title": "Commission Decision of 21\u00a0June 2012 appointing independent scientific experts to the Pharmacovigilance Risk Assessment Committee  Text with EEA relevance\n", "header": "22.6.2012 EN Official Journal of the European Union C 182/9\nCOMMISSION DECISION\nof 21 June 2012\nappointing independent scientific experts to the Pharmacovigilance Risk Assessment Committee\n(Text with EEA relevance)\n2012/C 182/06\nTHE EUROPEAN COMMISSION", "recitals": ",\nHaving regard to the Treaty on the Functioning of the European Union,\nHaving regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency\u00a0(1), and in particular Article 61a(1) thereof,\nWhereas:\n(1) Article 61a(1) of Regulation (EC) No 726/2004 requires that the Commission appoints six independent scientific experts as members of the Pharmacovigilance Risk Assessment Committee.\n(2) Article 61a(1) of Regulation (EC) No 726/2004 provides that the Commission is to appoint those members with a view to ensuring that the relevant expertise is available within the Committee.\n(3) In accordance with Article 61a(1) of Regulation (EC) No 726/2004, a public call for expression of interest has been undertaken by the Commission.\n(4) The members of the Committee are to be appointed for a period of three years starting on 2 July 2012, which may be prolonged once.\n(5) Where an independent scientific expert appointed by this decision is no longer capable of contributing efficiently to the work of the Committee, or resigns, the Commission may replace this member from the reserve list, for the remaining duration of the member\u2019s mandate,", "main_body": ["The following are hereby appointed members of the Pharmacovigilance Risk Assessment Committee for a term of three years from 2 July 2012:\n\u2014 Jane Ahlqvist RASTAD,\n\u2014 Marie Louise DE BRUIN,\n\u2014 Stephen J. W. EVANS,\n\u2014 Brigitte KELLER-STANISLAWSKI,\n\u2014 Herv\u00e9 LE LOUET,\n\u2014 Lennart WALDENLIND.", "The following are hereby placed on a reserve list by order of merit:\n\u2014 Thierry TRENQUE,\n\u2014 Michael THEODORAKIS,\n\u2014 Giampiero MAZZAGLIA,\n\u2014 Marie-Christine PERAULT-POCHAT,\n\u2014 Annemarie HVIDBERG HELLEBEK."], "attachments": "Done at Brussels, 21 June 2012.\nFor the Commission\nJohn DALLI\nMember of the Commission\n(1)\u00a0\u00a0OJ L 136, 30.4.2004, p. 1."}